Comprehensive Genomic Profiling of Advanced Anal Adenocarcinoma in Japan
JCO Precision Oncology · 2026
DOI: 10.1200/po-25-00562 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2026. Verfasst von Nozomu Ogura und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Anus Neoplasms, Adenocarcinoma. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Anal adenocarcinoma (AD) is a rare GI malignancy with no established standard treatment. Little is known about genomic alterations (GAs) and their therapeutic implications in advanced anal AD. Here, we compared the genomic profiles of advanced anal AD and advanced rectal AD. METHODS We retrospectively extracted data from patients with advanced anal or rectal AD who underwent comprehensive genomic profiling (CGP) and were registered at the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) in Japan. We examined somatic GAs, microsatellite instability (MSI) status, and tumor mutation burden (TMB). RESULTS From June 2019 to April 2023, 45 patients with anal AD and 1,915 patients with rectal AD were enrolled into the C-CAT database. TP53 (88.9%) and KRAS (51.1%) were the most common GAs in anal AD. Compared with rectal AD, anal AD showed significantly higher frequencies of ERBB3 (22.2% v 1.8%), MYC (20.0% v 8.4%), and BRCA2 (6.7% v 1.5%) alterations and a significantly lower frequency of APC mutations (8.9% v 84.6%). TMB-high status (≥10 mutations/Mb) was observed in 6.7% of anal AD cases, whereas no MSI-high tumors were identified in this group. At least one druggable GA (excluding RAS , BRAF V600E, ERBB2 , and MSI) was detected in 40.0% of patients with anal AD. Druggable GAs were identified in genes related to the MAPK pathway, DNA damage response pathway, and other oncogenic pathways. CONCLUSION Advanced anal AD exhibited a distinct genomic profile compared with advanced rectal AD. CGP is a useful approach for identifying druggable GAs in advanced anal AD to expand therapeutic opportunities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Jikei University School of Medicine, Tokyo, Japan.
- Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.
- Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan.
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
ORCID-Profile: Nozomu Ogura, Hidekazu Hirano, Kouya Shiraishi, Toshiharu Hirose, Hirokazu Shoji, Atsuo Takashima, Takafumi Koyama, Kan Yonemori, Ken Kato
Zitieren
APA
Ogura, N., Hirano, H., Shiraishi, K., Fujii, H., Hirose, T., Shoji, H., Okita, N., Takashima, A., Koyama, T., Yonemori, K., & Kato, K. (2026). Comprehensive Genomic Profiling of Advanced Anal Adenocarcinoma in Japan. JCO Precision Oncology. https://doi.org/10.1200/po-25-00562
Vancouver
Ogura N, Hirano H, Shiraishi K, Fujii H, Hirose T, Shoji H, et al. Comprehensive Genomic Profiling of Advanced Anal Adenocarcinoma in Japan. JCO Precision Oncology. 2026. doi:10.1200/po-25-00562
BibTeX
@article{Ogura2026,
author = {Ogura, Nozomu and Hirano, Hidekazu and Shiraishi, Kouya and Fujii, Hiroyuki and Hirose, Toshiharu and Shoji, Hirokazu and Okita, Natsuko and Takashima, Atsuo and Koyama, Takafumi and Yonemori, Kan and Kato, Ken},
title = {Comprehensive Genomic Profiling of Advanced Anal Adenocarcinoma in Japan},
journal = {JCO Precision Oncology},
year = {2026},
doi = {10.1200/po-25-00562}
}
EUVIMED